Gamida Cell

Cellular and Immune Therapies

Health Tech & Life Sciences
Acquired by Highbridge Capital Management on Mar 2024

Company Overview

Snapshot

Founded in February 1998, Gamida Cell operates with 51–200 employees and has raised over $416.22 million across 17 funding rounds from 15 investors. The company was acquired by Highbridge Capital Management in March 2024.

Business overview

Gamida Cell is a health tech and life sciences company focused on cellular and immune therapies. The company develops a diverse approach to cellular therapy using nicotinamide (NAM) to expand various cell types, including stem cells and natural killer (NK) cells, while preserving their original phenotype and potency. Its core product, Omisirge (omidubicel-onlv), is an allogeneic cell therapy approved by the FDA to reduce infection risk in blood cancer patients. Gamida Cell serves the pharmaceutical and healthcare industries, targeting patients with blood cancers and other conditions that can benefit from regenerative medicine and cell-based treatments.

Strategic signal

In March 2024, Gamida Cell was acquired by Highbridge Capital Management, marking a significant strategic shift for the company. This acquisition indicates a restructuring process and a new ownership structure, which could lead to changes in its operational focus and market strategy within the cellular therapy landscape.

Company Intelligence Q&A

What was the most recent significant corporate event for Gamida Cell?
Gamida Cell was acquired by Highbridge Capital Management in March 2024. This event was part of a restructuring process for the company.
When did Gamida Cell go public?
Gamida Cell completed its Initial Public Offering (IPO) on Nasdaq in October 2018, raising $50 million with a valuation of $210 million.
What was a key development regarding Gamida Cell's product, Omisirge, in late 2023?
In September 2023, the first patient received Gamida Cell's Omisirge™ (omidubicel-onlv), marking a significant milestone in the product's clinical application.
What were Gamida Cell's financial results for Q3 2023?
Gamida Cell reported its Third Quarter 2023 Financial Results and provided a company update in November 2023.
What is the status of Gamida Cell's natural killer (NK) cell therapy candidate GDA-201?
In October 2023, Gamida Cell reported preliminary data from its Phase 1 study of the natural killer (NK) cell therapy candidate GDA-201.

External links